142 related articles for article (PubMed ID: 32624359)
1. Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine.
Yu ZY; Tsai MJ; Lin YJ; Liu WD; Chou SC; Hung CC
J Microbiol Immunol Infect; 2020 Aug; 53(4):660-662. PubMed ID: 32624359
[No Abstract] [Full Text] [Related]
2. Disseminated gonococcal infection and eculizumab--a "high risk" connection?
Hublikar S; Maher WE; Bazan JA
Sex Transm Dis; 2014 Dec; 41(12):747-8. PubMed ID: 25581812
[TBL] [Abstract][Full Text] [Related]
3. Disseminated gonococcal infection in a patient with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
Niitsuma-Sugaya I; Kanamori H; Ichikawa S; Fukuhara N; Seike I; Takei K; Baba H; Oshima K; Aoyagi T; Harigae H; Tokuda K
Lancet Infect Dis; 2021 May; 21(5):741. PubMed ID: 33894850
[No Abstract] [Full Text] [Related]
4. Gonococcal septic shock associated with eculizumab treatment.
Gleesing J; Chiwane S; Rongkavilit C
Pediatr Infect Dis J; 2012 May; 31(5):543. PubMed ID: 22511000
[No Abstract] [Full Text] [Related]
5. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
McQuillen DP; Ram S
Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
[No Abstract] [Full Text] [Related]
6. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
7. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
8. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
Benz R; Krause M; Majer S; Taverna C; Herzog K
Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
[No Abstract] [Full Text] [Related]
9. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
10. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
[No Abstract] [Full Text] [Related]
11. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.
Pike A; Muus P; Munir T; Mitchell L; Arnold L; Riley K; Houghton N; Forrest B; Gachev J; Hillmen P; Griffin M
Br J Haematol; 2020 Oct; 191(1):e1-e4. PubMed ID: 32945525
[No Abstract] [Full Text] [Related]
13. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
14. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.
Crew PE; Abara WE; McCulley L; Waldron PE; Kirkcaldy RD; Weston EJ; Bernstein KT; Jones SC; Bersoff-Matcha SJ
Clin Infect Dis; 2019 Aug; 69(4):596-600. PubMed ID: 30418536
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
16. Meningococcemia in vaccinated patient under treatment with eculizumab.
Hernando Real S; Vega Castaño S; Pajares García R
Enferm Infecc Microbiol Clin; 2017 Mar; 35(3):200-201. PubMed ID: 26994815
[No Abstract] [Full Text] [Related]
17. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Röth A; Rottinghaus ST; Hill A; Bachman ES; Kim JS; Schrezenmeier H; Terriou L; Urbano-Ispizua Á; Wells RA; Jang JH; Kulasekararaj AG; Szer J; Aguzzi R; Damokosh AI; Shafner L; Lee JW
Blood Adv; 2018 Sep; 2(17):2176-2185. PubMed ID: 30171081
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
[TBL] [Abstract][Full Text] [Related]
19. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
20. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
Algado JT; Luque R; Nuñez R; Sanchez B
Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
